Prostate cancer: magnetic resonance imaging-targeted biopsy vs systematic biopsy

  • Kasivisvanathan V & al.
  • Eur Urol
  • 23 May 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In men with a clinical suspicion of prostate cancer, magnetic resonance imaging-targeted biopsy (MRI-TB) detects more clinically significant cancer and less clinically insignificant cancer and requires fewer biopsy cores compared with systematic biopsy.
  • MRI-TB is an attractive alternative diagnostic strategy to systematic biopsy for the diagnosis of prostate cancer.

Why this matters

  • MRI may be used to guide prostate biopsy cores to suspicious areas in the prostate.
  • In men with raised prostate-specific antigen, the traditional systematic biopsy with 10–12-core transrectal ultrasound (TRUS)-guided biopsy has been challenged by evidence from systematic reviews and randomised controlled trials (RCTs).

Study design

  • 76 studies (68 with a paired design and 8 RCTs) included 14,709 men, who met eligibility criteria, either received both MRI-TB and systematic biopsy or were randomly assigned to receive one of the tests.
  • Funding: None disclosed.

Key results

  • Pooled results of studies with paired-design showed that MRI-TB vs systematic biopsy detected more men with clinically significant cancer (detection ratio [DR], 1.16; 95% CI, 1.09-1.24) and fewer men with clinically insignificant cancer (DR, 0.66; 95% CI, 0.57-0.76; P<.0001 for both>
  • MRI-TB plus TRUS biopsy detected men with clinically significant cancer vs systematic biopsy alone (5 RCTs; DR, 1.21; 95% CI, 0.94-1.57), but the difference was not significant (P=.14).
  • MRI-TB plus TRUS biopsy vs TRUS biopsy alone did not differ in clinically insignificant cancer detection rates (4 RCTs; DR, 1.11, 95% CI, 0.49-2.51; P=.80).
  • The proportion of cores positive for cancer was greater for MRI-TB vs systematic biopsy (relative risk [RR], 3.17; 95% CI, 2.82-3.56; P<.0001>

Limitations

  • Risk of bias.
  • Substantial between-study variability.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit